|
|
|
|
||
biopharmas stuck to licensing and research partnerships this at JPM I think IMGN falls in category of going it alone due to small population and tight label which lessens the need for Big Pharma. It's not difficult to hire 5 - 10 reps to cover the EU.
But what was made public is that biopharmas stuck to licensing and research partnerships this week at JPM, extending a trend that has been going on for months. Backloaded, billion-dollar biobucks pacts are increasingly standard. “This year, I think, is a reflection of last year, and it’s much more licensing, much more tie-up,” said Stuart Henderson, global life sciences industry leader at Accenture, in an interview with Fierce Biotech. There are a few key factors driving the focus on licensing and collaborations, according to Henderson. Premiums on acquisitions have increased, thus limiting affordability; venture capital funding has skyrocketed three times in the past five years, reducing the need for pharma’s money; biotechs are going all the way to market on their own with tighter labels and more defined populations, shrinking the need for pharma’s help in selling drugs; and the economic value of Big Pharma buying a late-stage biotech “has declined,” he said. |
return to message board, top of board |